MAP2K7 and non-small cell lung carcinoma: For instance, in non small cell lung cancer with oncogenic activated EGFR, the activation of MEK/ERK1/2 in combination with Smad3 and mTOR promotes resistance to cisplatin, induces the EMT program, and up-regulates PD-1L.